Quantcast

Latest Actavis Stories

2014-05-14 08:31:00

- Paul Bisaro to Assume Newly Created Role as Executive Chairman - DUBLIN, May 14, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year. Following the close, Paul Bisaro, Chairman and Chief Executive Officer of Actavis, will become Executive Chairman. Brent Saunders,...

2014-05-13 16:29:25

DUBLIN, May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo(®) (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity....

2014-05-13 16:29:15

DUBLIN, May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 in New York City. The presentation will take place on Thursday, May 29, 2014 at 10:00 a.m. Eastern Time at the Waldorf-Astoria Hotel, 301 Park Avenue, New York, NY. To...

2014-05-12 16:29:38

LAVAL, Quebec, May 12, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that certain of its subsidiaries have entered into settlement agreements with affiliates of Actavis plc related to Actavis' generic versions of Acanya® Gel, 1.2%/2.5%, and Tiazac ® XC. Valeant's subsidiaries, Dow Pharmaceuticals Sciences, Inc. and Valeant Pharmaceuticals North America LLC, and Actavis' subsidiary, Watson Laboratories, Inc., entered into...

2014-05-12 08:31:42

DUBLIN, May 12, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya(® )(clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%. Acanya(®) Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris. Under the terms of the agreement, Valeant will grant...

2014-05-09 08:26:36

ST. LOUIS, May 9, 2014 /PRNewswire-USNewswire/ -- Today, K-V Pharmaceutical Company ("KV") announced that Paul Williams - a seasoned executive with extensive experience in both neonatal health and the bio-pharmaceuticals business - has joined the company to lead its Women's Healthcare Division. KV recently underwent a broader reorganization of the Company's operations, creating two new business units: the Women's Healthcare Division, led by Williams, and the Maternal Health Division, led by...

2014-05-05 08:29:56

-- Companies Schedule Shareholder Meetings for June 17, 2014 -- DUBLIN and NEW YORK, May 5, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC") by Actavis plc on March 25, 2014 and amended on May 2, 2014 (the "Form S-4"), which includes a joint proxy statement of Actavis and Forest, was declared effective on May 2, 2014. The...

2014-04-30 08:32:07

- First Quarter 2014 GAAP Earnings Per Diluted Share of $0.55 - DUBLIN, April 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billion in the first quarter 2013. On a non-GAAP basis, diluted earnings per share for the first quarter 2014 increased to $3.49, compared to $1.99 per diluted share in the first quarter 2013. GAAP earnings per diluted share for the first...

2014-04-29 08:34:05

BOSTON, April 29, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company") today announced financial results for the three-month period ended March 31, 2014. First Quarter 2014 Financial Highlights -- Total revenues grew 15% to $7.2 million compared to $6.3 million in the first quarter of 2013; -- Cash flow from operations increased to $0.9 million as compared with $0.7 million in the first quarter of 2013; -- Repurchased...

2014-04-28 16:31:49

DUBLIN, April 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration (FDA) challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex(®) (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules. Actavis maintains that the FDA improperly awarded sole exclusivity on generic Celebrex(®) to...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related